INNOVIVA, INC. Shareholders' Equity
INNOVIVA, INC. (INVA) had Shareholders' Equity of $1.23 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.23B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.34B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.17B.
- 2024-12-31: Stockholders' Equity Attributable to Parent $691.16M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.23B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.34B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.17B 10-Q · filed 2026-08-05 |
| 2024-12-31 | $691.16M 10-K · filed 2026-02-25 |
| 2022-12-31 | $565.79M 10-K · filed 2023-02-28 |
| 2022-09-30 | $641.37M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $388.34M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $386.64M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $414.74M 10-K · filed 2023-02-28 |
| 2021-09-30 | $402.81M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $329.78M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $634.46M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $539.91M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $485.56M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $456.91M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $379.54M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $313.50M 10-K · filed 2021-02-25 |
| 2019-09-30 | $267.06M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $226.68M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $188.25M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $153.58M 10-K · filed 2020-02-19 |
| 2018-09-30 | -$111.36M 10-Q · filed 2018-10-31 |
| 2018-06-30 | -$157.36M 10-Q · filed 2018-07-26 |
| 2018-03-31 | -$213.56M 10-Q · filed 2018-05-04 |
| 2017-12-31 | -$242.86M 10-K · filed 2019-02-19 |
| 2017-09-30 | -$222.96M 10-Q · filed 2017-11-03 |
| 2017-06-30 | -$296.73M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$334.19M 10-Q · filed 2017-05-05 |
| 2016-12-31 | -$352.99M 10-K · filed 2018-02-23 |
| 2016-09-30 | -$367.86M 10-Q · filed 2016-11-03 |
| 2016-06-30 | -$363.10M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$361.97M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$342.64M 10-K · filed 2017-02-28 |
| 2015-09-30 | -$323.00M 10-Q · filed 2015-11-05 |
| 2015-06-30 | -$293.99M 10-Q · filed 2015-08-06 |
| 2015-03-31 | -$260.14M 10-Q · filed 2015-05-08 |
| 2014-12-31 | -$223.35M 10-K · filed 2017-02-28 |
| 2014-09-30 | -$193.14M 10-Q · filed 2014-11-04 |
| 2014-06-30 | -$187.53M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $263.25M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $299.12M 10-K · filed 2017-02-28 |
| 2013-09-30 | $330.05M 10-Q · filed 2013-11-01 |
| 2013-06-30 | $85.65M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $91.51M 10-Q · filed 2013-05-01 |
| 2012-12-31 | $155.03M 10-K · filed 2016-02-24 |
| 2012-09-30 | $173.29M 10-Q · filed 2012-10-31 |
| 2012-06-30 | $189.26M 10-Q · filed 2012-08-01 |
| 2012-03-31 | $6.13M 10-Q · filed 2012-05-02 |
| 2011-12-31 | -$87.05M 10-K · filed 2015-02-27 |
| 2011-09-30 | -$59.15M 10-Q · filed 2011-11-02 |
| 2010-12-31 | -$22.42M 10-K · filed 2014-03-03 |
| 2009-12-31 | -$188.99M 10-K · filed 2013-02-26 |
| 2008-12-31 | -$134.95M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |